Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
| MarketCap | 83.9M |
|---|---|
| PE Ratio | |
| PEG Ratio | 0.6 |
| P/B | 1.7 |
| P/S (ttm) | 12.5 |
| Earning Growth (QoQ) | |
| Revenue Growth (QoQ) | |
| Short % | 7% |
| Held by Institutions % | 63% |
| 1 Day Vol Adjusted Return | -0.7 |
| 1 Month Vol Adjusted Return | 5.6 |
| 3 Month Vol Adjusted Return | -0.6 |
| 6 Month Vol Adjusted Return | -5.8 |
| 20 Days SMA Price ZScore | -0.7 |
| 50 Days SMA Price ZScore | -0.3 |
| 12 -26 Days PPO | 1.7 |
| 1 Month Average Short Volume Ratio | 29.9 |
| 1 Day Volume Change ZScore | -0.3 |
| 1 Month Daily Vol | 5.7 |
Stock news
Homology Medicines Inc (NASDAQ: FIXX) expects to provide initial data from the pheEDIT trial of HMI-103 for phenylketonuria (PKU) in mid-year 2023. There are nine active clinical trial sites, with more expected to be initiated throughout 2023. The juMPStart Phase 1 gene therapy trial for Hunter syndrome (MPS II) has five clinical sites in the U.S. and Canada, with more expected to be initiated, and initial data is expected in 2H of 2023. Homology shared new preclinical data supporting the immuno
Strong Cash Position with Runway into Fourth Quarter 2024 Non-Clinical Data on Immunosuppression Regimen Supportive of Clinical Programs Preclinical Data from HMI-103 Gene Editing Program Utilizing a Unique Mechanism of Action Demonstrated Significantly Increased Potency in PKU Model BEDFORD, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today enrollment and site status updates from the pheEDIT Phase 1 gene editing trial
Homology Medicines ( NASDAQ:FIXX ) Third Quarter 2022 Results Key Financial Results Net loss: US$33.7m (loss widened by...
Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- On Track for Updates on pheEDIT and juMPStart Programs by Year-End - - Strong Financial Position with Cash Runway into Fourth Quarter 2024 - - Promoted Albert Seymour, Ph.D., to Chief Executive Officer Driving Clinical Trials and Genetic Medicines Platform Forward for Patients - BEDFORD, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the third quarter ended September 30, 2022, and highlighted
- Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design - BEDFORD, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a presentation on the design of pheEDIT, a Phase 1, open-label, dose-escalation study evaluating one-time gene editing candidate HMI-103 in adults with phenylketonuria (PKU). The presentation included preclinical data demonstrating efficacy in a PKU m
BEDFORD, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, announced today participation at the following conferences. Cell & Gene Meeting on the Mesa Corporate presentation given by Albert Seymour, Ph.D., President and Chief Executive Officer of Homology, on October 11 at 3:15 p.m. PT“Gene Editing Accelerates: The First Generation Nears Approval While New Approaches Progress Through the Clinic” panel featuring Dr. Seymo
Enhancing the depth of 5AM’s scientific and operational expertiseSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science opportunities throughout North America and Europe from its $450 million 5AM Ventures VII fund and its $300 million 5AM Opportunities II fund, whi
Here's The Petri Dish, a roundup of news that may get overlooked amid the influx of health care happenings. This week: Homology gets a new CEO, Gingko and Flagship join a lobbying group and more.